The recent decision in 2025 U.S. Dist. LEXIS 103623 (N.D. Cal. May 20, 2025), highlights the complexities of ERISA litigation, particularly regarding delegation of discretionary authority and the implications for judicial review. This blog explores the facts, legal holdings, and broader implications of the court’s ruling.

Case Background: From Disability to Dispute

Daniel C., a Chevron employee, initially sought short-term disability leave in October 2017 due to major depressive disorder and workplace conflicts. Chevron’s third-party claims administrator, ReedGroup, approved the request. However, Daniel’s circumstances changed dramatically when he was struck by a vehicle on December 31, 2017, resulting in a traumatic brain injury and a ten-day coma. In June 2018, Daniel applied for long-term disability (LTD) benefits, citing his brain injury as the primary cause of his disability. ReedGroup approved the benefits through June 2020 but later denied further benefits, citing insufficient medical documentation and the exhaustion of mental health-related disability limits. The parties agreed that Chevron’s plan document vested the company with discretionary authority and permitted delegation of that authority. However, they disagreed about whether Chevron had properly delegated such authority to ReedGroup. This distinction proved crucial, as proper delegation would result in deferential arbitrary and capricious review, while improper delegation would trigger the more demanding de novo standard.

Delegation of Authority: A Procedural Misstep

One of the central issues in the case was whether Chevron had properly delegated discretionary authority to ReedGroup, which would determine the standard of judicial review. Under ERISA, courts apply de novo review to benefit denials unless the plan explicitly grants discretionary authority to the administrator. While Chevron’s plan document allowed for delegation, the court found that Chevron failed to meet ERISA’s requirement for a written instrument specifying the fiduciary responsibilities delegated to ReedGroup.

The court’s analysis focused on ERISA’s specific requirements for delegating fiduciary responsibilities. Under federal law, any delegation of fiduciary responsibilities must occur pursuant to a written instrument that specifies the fiduciary responsibilities so delegated to each such person. The court emphasized that naming ReedGroup in the Summary Plan Description (SPD) alone could not satisfy this requirement.

The court relied heavily on the Supreme Court’s decision in CIGNA Corp. v. Amara, 563 U.S. 421 (2011), which established that SPDs do not themselves constitute the terms of the plan. The court distinguished the case from Mull v. Motion Picture Industry Health Plan & Bd. of Dirs. of MPI Health Plan, 2019 U.S. Dist. LEXIS 212081, where the Ninth Circuit found an SPD could constitute plan terms, noting that in Mull there was no separate plan document and the SPD explicitly stated it constitutes both the Plan document and the Summary Plan Description.

Thus, even though Chevron argued that the SPD functions as the designation instrument, communicating to plan participants the name of the entity that serves as the claims administrator and decides all claims, the court rejected this argument, finding that the SPD could not function as the delegation instrument because it did not specify the fiduciary responsibilities delegated to ReedGroup. The court emphasized that naming ReedGroup in the SPD was insufficient to constitute a valid delegation. The SPD lacked specific language identifying the fiduciary responsibilities delegated to ReedGroup, and the court noted that SPDs are not formal plan documents under ERISA unless they specifically state that they are part of the plan documents. See Krebsbach v. Travelers Pension Plan, 2024 U.S. Dist. LEXIS 206671; Collins v. Life Ins. Co. of N. Am., 2023 U.S. Dist. LEXIS 50683. This failure to properly delegate authority in the plan itself, as opposed to the SPD, led the court to apply de novo review, a more rigorous standard that favors claimants.

Implications of De Novo Review

The court’s decision to apply de novo review stripped ReedGroup’s denial of benefits of the deference typically afforded under the arbitrary and capricious standard. Under de novo review, the court independently evaluates the evidence without deferring to the administrator’s decision. This shift in the standard of review often benefits claimants, as it allows for a more thorough examination of the evidence supporting their claims.

The court’s ruling also underscores the importance of compliance with ERISA’s technical requirements for delegation. Plan sponsors must ensure that any delegation of discretionary authority is clearly documented in a formal written instrument that meets ERISA’s standards.

Broader Implications for Plan Administrators

This case serves as a cautionary tale for plan administrators and sponsors. The court’s strict interpretation of ERISA’s delegation requirements suggests that informal arrangements or general references in SPDs will not suffice. Plan sponsors must carefully document delegation arrangements to avoid procedural pitfalls that could lead to unfavorable judicial review standards. Additionally, the decision highlights the potential financial consequences of procedural missteps.

Procedural Outcome and Next Steps

The court’s denial of summary judgment for both parties reflects the complexity of the issues and the need for further factual development under the de novo standard. The case has been remanded for additional proceedings, with a hearing scheduled for August 2025. This procedural outcome demonstrates the challenges of resolving ERISA disputes, particularly when the standard of review is contested.

Conclusion: Lessons for Practitioners

The decision underscores the importance of precision in ERISA delegation procedures and the potential impact of procedural victories in litigation. For plan sponsors, the case serves as a reminder to ensure compliance with ERISA’s technical requirements to avoid unfavorable outcomes. For claimants, the decision highlights the value of pursuing procedural challenges, as even partial success can lead to significant advantages, including attorney’s fees, which were awarded in a later decision by the Court. As ERISA litigation continues to evolve, practitioners must remain vigilant in navigating the procedural and substantive complexities of these cases.